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Abstract
Background: Early provision of palliative care, at least 3–4 months before death, can improve patient quality of life
and reduce burdensome treatments and financial costs. However, there is wide variation in the duration of
palliative care received before death reported across the research literature. This study aims to determine the
duration of time from initiation of palliative care to death for adults receiving palliative care across the international
literature.
Methods: We conducted a systematic review and meta-analysis that was registered with PROSPERO
(CRD42018094718). Six databases were searched for articles published between Jan 1, 2013, and Dec 31, 2018:
MEDLINE, Embase, CINAHL, Global Health, Web of Science and The Cochrane Library, as well undertaking citation
list searches. Following PRISMA guidelines, articles were screened using inclusion (any study design reporting
duration from initiation to death in adults palliative care services) and exclusion (paediatric/non-English language
studies, trials influencing the timing of palliative care) criteria. Quality appraisal was completed using Hawker’s
criteria and the main outcome was the duration of palliative care (median/mean days from initiation to death).
Results: One hundred sixty-nine studies from 23 countries were included, involving 11,996,479 patients. Prior to
death, the median duration from initiation of palliative care to death was 18.9 days (IQR 0.1), weighted by the
number of participants. Significant differences between duration were found by disease type (15 days for cancer vs
6 days for non-cancer conditions), service type (19 days for specialist palliative care unit, 20 days for community/
home care, and 6 days for general hospital ward) and development index of countries (18.91 days for very high
development vs 34 days for all other levels of development). Forty-three per cent of studies were rated as ‘good’
quality. Limitations include a preponderance of data from high-income countries, with unclear implications for low-
and middle-income countries.
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Conclusions: Duration of palliative care is much shorter than the 3–4 months of input by a multidisciplinary team
necessary in order for the full benefits of palliative care to be realised. Furthermore, the findings highlight inequity
in access across patient, service and country characteristics. We welcome more consistent terminology and
methodology in the assessment of duration of palliative care from all countries, alongside increased reporting from
less-developed settings, to inform benchmarking, service evaluation and quality improvement.
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Background
Palliative care aims to improve the quality of life of pa-
tients with life-limiting illnesses through prevention and
relief of suffering [1]. Recent systematic reviews and
meta-analyses demonstrate that early integration of spe-
cialist palliative care can improve quality of life for pa-
tients with advanced, incurable illness, including
reducing symptom intensity, hospitalisation, aggressive
treatments and associated costs at the end of life [2–4].
Studies included patients with malignant and non-
malignant disease. Definitions of early integration vary.
Although there is a paucity of well-conducted rando-
mised controlled trials (RCTs) with mixed findings
across trials, evidence suggests that ‘for full benefits of
palliative care to be realized, continuity by a multidiscip-
linary team is needed for at least 3–4 months’ [5] to
realise maximum benefit.
The 2018 Lancet Commission on Palliative Care and
Pain Relief identified a lack of palliative care and pain re-
lief globally [6]. By 2060, the burden of serious health-
related suffering is expected to increase almost twofold,
most rapidly in low-income countries [7]. Studies report-
ing on the duration of palliative care vary (e.g. from a
median of 18–57 days and mean of 30–70 days), and
suggest that early integration is not routine practice [8–19].
To date, there have been no attempts to systematically
summarise reports on the duration of palliative care
across the research literature. Doing so with a global
focus could allow local and national services to bench-
mark using an international standard, determine country
variations reflecting differences in wealth and palliative
care development, and would identify the gap between
current routine practice and the ideal duration of 3–4
months of palliative care.
This systematic review aims to identify studies report-
ing on the time interval between initiation of specialised
palliative care services and death for adult patients
within routine clinical practice and to explore associated
patient, service and country characteristics which influ-
ence this duration.
Methods
We conducted a systematic review and meta-analysis.
The study protocol was registered with PROSPERO
(CRD42018094718) on 30 April 2018. Ethics approval
was not required for this secondary data analysis.
Data sources and searches
Databases searched included MEDLINE (1946 to January
2019), Embase (1947 to January 2019), CINAHL (1960
to January 2019), Global Health (1973 to January 2019),
Web of Science (1990 to January 2019) and The
Cochrane Library. We conducted database searches on 2
October 2017 with additional updates on 12 February
2018 and 15 January 2019. The search strategy included
terms for palliative care, duration of palliative care and
referral (see example MEDLINE strategy provided in
Additional file 1: Fig S1). Additional studies were identi-
fied through hand-searching of reference and citation
lists of included studies. Search strategies (e.g. Add-
itional file 1: Fig S1) were used to conduct a scoping
search in October 2020 to determine whether any eli-
gible population-based or large-scale studies had been
published since January 2019. Of the 667 abstracts iden-
tified, no eligible population-based or large studies were
identified so an updated extraction and analysis includ-
ing data from 2019 was not undertaken.
Study selection
Studies were included if they reported on adult patients
(≥ 18 years old) referred to or admitted under adult pal-
liative care services. Palliative care services were defined
as healthcare services which either self-define as special-
ist palliative care services or solely or majorly practise
palliative care. These services could be in any setting in-
cluding general hospital wards, specialist inpatient units/
hospices or community settings (outpatients/day units/
home care). Studies were only included if they reported
length-of-stay in a specialist inpatient palliative care unit,
referral-to-death time interval in any setting or survival
time after palliative care referral. We limited search re-
sults to studies published from 1 January 2013 to 31 De-
cember 2018 to reflect contemporary practice. Included
studies could be of any study design. Unpublished study
data were included after contact with study investigators.
Studies were excluded if they included children (< 18
years old) or referrals to paediatric palliative care ser-
vices and did not report adult data separately, reported
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on referrals solely to bereavement services or non-
palliative care services, were randomised trials where the
intervention influenced the timing of palliative care or
were not in the English language.
Data extraction and quality assessment
Three authors (RIJ/CEJ/HLE) independently screened
10% of the titles and abstracts of studies identified. Dis-
crepancies in screening inclusion and exclusion were re-
solved through discussion, and then review by a fourth
author (MJA). As concordance between authors was
greater than 90%, each author screened a portion of the
remaining abstracts alone (assigned randomly and evenly
distributed). Full-text articles were assessed for eligibility
and, if included, data extraction was performed using a
piloted form by three independent authors (RIJ/YE/
HLE).
Data were extracted from each study on the following
sample and methodological characteristics: country of
origin, country level of human development according
to the UNDP Development Index, country palliative care
development level according to the WHPCA categorisa-
tion of palliative care development, study design, num-
ber of patients, percentage of patients alive at the end of
the study period, summaries of age, gender and ethnicity
(% White Caucasian) of study participants, each cohort’s
type of disease, type of palliative care service referred to,
the geographical level of analysis for each study (local,
regional, national, international), the statistical summary
of duration in days (mean, median or both) and termin-
ology used to describe the duration of palliative care
(survival, referral-to-death, length of stay). We extracted
data on the primary outcome of the duration of pallia-
tive care before death in days (median or mean). In-
cluded study authors were contacted for missing data.
Study quality of individual studies was assessed using
Hawker’s criteria for reviewing disparate observational
data systematically [20]. The criteria consist of 9 items,
each with a score of 1–4 (total score of 36). We rated
studies with scores of ≤ 18 as poor, 19–27 as fair and
> 27 as good, consistent with Boer et al.’s approach
[21]. Four authors piloted the criteria with 10% of the
included studies, with concordance of > 90% achieved
prior to individual allocation of remaining studies
(RIJ/MJA/YE/EJC).
Data synthesis and analysis
A meta-analysis was performed to synthesise reporting
of the median number of days palliative care was initi-
ated prior to death. We used the median as the preferred
measure of central tendency as it is less affected by out-
liers and better reflects skewed data. The number of days
from palliative care initiation to death was reported
across the included articles in one of three ways: as a
median, as a mean or including both a median and mean
value. For studies reporting mean values only, linear re-
gression modelling was used to derive a median value
(see Additional file 1: Fig S2). This was calculated
through examining the relationship between mean and
median values in articles where both values were re-
ported. The trend line was then applied to derive median
values where included studies only reported a mean
number of days from palliative care initiation to death.
We then weighted median values for each study accord-
ing to the number of study participants it contained. We
then combined median values from all studies to calcu-
late a final weighted median value and the interquartile
range (IQR) to summarise duration of palliative care.
Additional analyses were performed to investigate the
impact of country level of human development (United
Nations Development Programme Human Development
Index categories of very high, high, medium, low, other),
country level of palliative care development (Worldwide
Hospice Palliative Care Alliance 2011 categorisation of
palliative care development using 1, 2, 3a, 3b, 4a, 4b), type
of disease (malignant, non-malignant, mixed) and type of
setting of the palliative care service (specialist palliative
care unit, community/home, combined, general hospital
ward, unspecified) on the duration of palliative care. We
used the Mann-Whitney U test to compare the distribu-
tion of medians using a significance level of p = 0.05.
Sensitivity analyses were performed to assess the ro-
bustness of the primary outcome. Sensitive analyses were
undertaken to determine the impact of the characteris-
tics of included studies on the overall weighted median
duration of palliative care derived from all studies. A
number of characteristics were identified for sensitivity
analysis. These included studies where the mean dur-
ation of palliative care had been converted to a median
value, studies with small sample sizes (< 100 partici-
pants), studies analysing local and regional data (defined
as ≥ 1 centres in the same geographical region within
one country), studies reporting > 5% survival at the end
of the study period, studies reporting length-of-stay in
palliative care units and studies with poor/fair ratings for
methodological quality. For each characteristic included
in the sensitivity analyses, we identified all studies with
the characteristic of interest (e.g. studies with small sam-
ple sizes < 100 participants), removed data from all stud-
ies with the characteristic, and then recalculated the
final weighted median value with interquartile
range (IQR) and median absolute deviation (MAD) to
summarise duration of palliative care less the data from
studies with the characteristic being explored. This en-
abled us to explore the influence of characteristics of
interest on the overall weighted median duration of pal-
liative care. We also conducted a post hoc analysis ex-
cluding the USA (United States of America) studies,
Jordan et al. BMC Medicine          (2020) 18:368 Page 3 of 25
given differences found between studies from and out-
side of the USA.
We used IBM SPSS Statistics 22 for data analysis.
Reporting is aligned with the PRISMA checklist for
reporting systematic reviews and meta-analyses (see
Additional file 2: Table S1).
Results
Two thousand six hundred sixty studies were screened,
with 169 studies included in the systematic review and
meta-analysis. Studies were excluded at the screening
stage as their titles/abstracts did not meet the inclusion
criteria broadly. Reasons for exclusion at the final eligi-
bility stage are outlined in Fig. 1.
Table 1 summarises the individual characteristics of
the included studies. All included studies were used in
the meta-analysis.
A table summarising study characteristics can be
found in Additional file 2: Table S1. The total number of
study participants was 11,996,479. Eighty-eight per cent
of studies were observational and retrospective, and
most studies were descriptive rather than analytical. The
source of publications was predominantly the USA,
which accounted for 85% of studies and 97% of partici-
pants. Most studies (and 99% of participants) were from
very high development countries (94%) and those with
the greatest level (4b) of palliative care development
(83%). Patients had a weighted mean age of 81.7 years
with an equal distribution of males-to-females. Ethnicity
was only reported in 38% of studies, stating 88% of study
participants as white Caucasian. Most studies reported
patients with malignant (50%) or non-malignant disease
(12%). However, studies that reported a combined case-
mix (35%) covered 91% of total participants. Similarly,
half of the studies reported on specific types of palliative
Fig. 1 PRISMA flowchart outlining article selection
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care services (31% SPCU, 11% community/home and 7%
hospital), with studies reporting in combined settings
(50%) accounting for 95% of all participants.
Of all included articles, 46 (27%) were length-of-stay
studies. The proportion of patients alive at the end of
each study is outlined in Table 1. In 28 of the length-of-
stay studies (60.9%) fewer than 10% of patients were
alive, with 22 (47.8%) having no patients alive at the end
of study.
Study quality was rated as good in 73 (43%) studies,
fair in 90 (53%) and poor in 5 (3%). Studies rated as
good accounted for 64% of total participants although
studies variably summarised the duration of palliative
care with inconsistent measures of spread. A table of in-
dividual study quality appraisals can be found in Add-
itional file 2: Table S3.
The weighted median duration of palliative care until
death was 18.9 days (IQR 0.09, Table 2). Three studies
had more than one million participants each [48, 113,
159]. The median duration of palliative care excluding
these studies (total 16.7% participants) was 19.2 days
(IQR 15). The weighted median duration in days until
death per country, by service type, disease type, WHPCA
level of palliative care development, and UNDP Human
Development Index is reported in Table 2.
Analyses of the influence of study characteristics on
the overall weighted median duration of palliative care
until death are outlined in Additional file 2: Table S4.
Studies rated as poor and fair did not significantly adjust
the duration of palliative care for the whole dataset, but
they significantly reduced the duration of palliative care
when looking at non-USA studies alone. Studies tended
to report longer mean than median durations where
both were used, reflecting positively skewed data. Studies
in which mean durations were converted to medians did
not affect the outcome for the whole dataset, but did sig-
nificantly increase the duration of palliative care for
non-USA studies. Even excluding studies with more
than one million participants did not greatly alter the
duration of palliative care (i.e. 19.2 days).
The spread of median duration of palliative care values
according to sample size is demonstrated in Figs. 2 and 3.
Figure 2 outlines the difference in median days dur-
ation of palliative care prior to death according to coun-
try level of human development and palliative care
development. Studies from countries with a very high
level of human development had a shorter duration of
palliative care than less developed countries (18.9 vs.
34.0 days, p < 0.001). Similarly, as shown in Fig. 3, studies
from countries with the greatest level of palliative care
development had a shorter duration of palliative care
than countries with lower levels (18.9 vs. 28.0 days, p <
0.001). Not all studies reported duration of palliative
care for patients with both malignant and non-
malignant disease, and across a combination of palliative
care settings. Consequently, we conducted sub-analyses
using data on the type of disease available in 105 of the
included studies (i.e. 62.1%) and the type of palliative
care setting using data from 82 studies (i.e. 48.5%). The
median duration of palliative care was nine days longer
for studies reporting on patients with malignant disease
compared with non-malignant disease (15.0 vs. 6.0, p <
0.001). Studies conducted in specialist palliative care
units and community/home settings reported a similar
duration of palliative care, both longer than in general
hospital ward settings (19.2 vs. 20.0 vs. 6.0 days, respect-
ively, p < 0.001). A further sub-analysis, comparing data
from the USA and non-USA countries, was performed
given the preponderance of data from the former. The
median duration of palliative care in studies from the
USA was ten fewer days than in non-USA studies (18.9
vs. 29.0, p < 0.001).
The median duration of palliative care was unaffected
by studies reporting local or regional data, reporting
duration of palliative care as a mean solely, reporting
length-of-stay, studies with < 100 participants and stud-
ies rated as fair or poor quality. It was, however, reduced
to 14.71 days (IQR 0.83; MAD 8.23) after excluding
studies with > 5% participants alive at the end of the
study period. Sensitivity analysis showed that studies
rated as poor and fair did not significantly adjust the
duration of palliative care for the whole dataset, but they
significantly reduced the duration of palliative care when
looking at non-USA studies alone.
Given differences between studies from and outside of
the USA, we hypothesised that non-USA studies may
have different factors influencing the duration of pallia-
tive care. We conducted additional analyses excluding
USA data (Additional file 2: Tables S4 and S5). Studies
from non-USA countries with a very high level of hu-
man development still had a shorter duration of pallia-
tive care than less developed countries (29.0 vs. 34.0
days, p < 0.001). However, studies from non-USA coun-
tries with the greatest level of palliative care develop-
ment had a longer duration of palliative care than
countries with lower levels of palliative care develop-
ment (68.9 vs. 28.0 days, p < 0.001). Studies involving pa-
tients with malignant disease reported a longer duration
of palliative care than those with non-malignant disease;
however, the difference was smaller (28.0 vs. 24.3 days,
p < 0.001). Studies conducted in community or home
settings had a longer duration of palliative care than
those conducted in specialist palliative care units and
general hospital ward settings (47.9 vs. 14.8 vs. 6.0 days,
respectively, p < 0.001).
The sensitivity analyses showed the median duration
of palliative care for non-USA studies was unaffected by
length-of-stay, studies with < 100 participants, and
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Table 2 Duration of palliative care in days prior to death, by country and other characteristics
Weighted median duration of
palliative care in days (IQR)
p value
All studies 18.91 (0.09)
Country Service type
Australia 6.00 (8.81)
Specialist palliative care 14.81 (0.00)
Community/home -
General hospital ward 6.00 (0.00)
Combined 25.00 (0.00)
Austria 9.00 (0.00)
Specialist palliative care 16.00 (5.00)
Community/home -
General hospital ward -
Combined 9.00 (0.00)
Belgium 17.95 (*†)
Specialist palliative care -
Community/home -
General hospital ward -
Combined 17.95 (0.00)
Brazil 34.00 (0)
Specialist palliative care -
Community/home 115.02 (0.00)
General hospital ward -
Combined 34.00 (0.00)
Canada 68.88 (0.00)
Specialist palliative care 25.60 (3.73)
Community/home 47.92 (0.00)
General hospital ward 6.00 (0.00)
Combined 68.88 (0.00)
China 19.00 (*†)
Specialist palliative care 19.00 (0.00)
Community/home -
General hospital ward -
Combined -
Denmark 29.00 (*†)
Specialist palliative care -
Community/home -
General hospital ward -
Combined 29.99 (0.00)
Egypt 66.00 (*†)
Specialist palliative care 66.00 (0.00)
Community/home -
General hospital ward -
Combined -
Finland 25.37 (*†)
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Table 2 Duration of palliative care in days prior to death, by country and other characteristics (Continued)
Weighted median duration of
palliative care in days (IQR)
p value
Specialist palliative care 25.37 (0.00)
Community/home -
General hospital ward -
Combined -
France 22.00 (0.00)
Specialist palliative care -
Community/home -
General hospital ward -
Combined 22.00 (0.00)
Germany 13.16 (0)
Specialist palliative care 13.16 (0.00)
Community/home -
General hospital ward -
Combined -
Ireland 46.27 (0.00)
Specialist palliative care -
Community/home -
General hospital ward 10.30 (0.00)
Combined 46.27 (0.00)
Italy 21.00 (10.00)
Specialist palliative care 11.62 (6.26)
Community/home 92.00 (0.00)
General hospital ward -
Combined 21.00 (0.00)
Japan 28.95 (0.95)
Specialist palliative care 28.95 (0.00)
Community/home 35.00 (0.00)
General hospital ward -
Combined 28.00 (0.00)
Netherlands 36.00 (37†)
Specialist palliative care 36.00 (0.00)
Community/home -
General hospital ward -
Combined -
Saudi Arabia 16.63 (*†)
Specialist palliative care -
Community/home -
General hospital ward -
Combined 16.63 (0.00)
Singapore 8.00 (19†)
Specialist palliative care -
Community/home -
General hospital ward -
Combined 8.00 (0.00)
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Table 2 Duration of palliative care in days prior to death, by country and other characteristics (Continued)
Weighted median duration of
palliative care in days (IQR)
p value
South Korea 22.18 (0.00)
Specialist palliative care 22.18 (0.00)
Community/home -
General hospital ward -
Combined 32.63 (0.00)
Spain 43.52 (0.00)
Specialist palliative care -
Community/home 43.52 (0.00)
General hospital ward -
Combined -
Taiwan 28.00 (0.00)
Specialist palliative care 13.50 (0.00)
Community/home -
General hospital ward 33.71 (0.00)
Combined 28.00 (0.00)
Thailand 33.00 (*†)
Specialist palliative care -
Community/home -
General hospital ward -
Combined 33.00 (0.00)
Turkey 24.88 (12.35)
Specialist palliative care 24.88 (12.35)
Community/home -
General hospital ward -
Combined -
UK 48.00 (0.00)
Specialist palliative care 9.00 (2.40)
Community/home 41.41 (294.59)
General hospital ward -
Combined 48.00 (0.00)
Multicentre – USA & Brazil 6.00 (5†)
Specialist palliative care 6.00 (0.00)
Community/home -
General hospital ward -
Combined -
USA 18.91 (0.09)
Specialist palliative care 19.20 (17.72)
Community/home 20.00 (0.00)
General hospital ward 3.00 (12.01)
Combined 18.91 (0.09)
USA vs non-USA studies USA 18.91 (0.09) p < 0.001
All non-USA studies 29.00 (40.88)
UNDP Human Development Index (2015) Very high 18.91 (0.09)
High 34.00 (0)
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studies with > 5% of cohorts alive at the end of the study
periods. However, it was reduced to 28.0 days after ex-
cluding local and regional studies (IQR 1.00; MAD 8.00)
and studies reporting duration of palliative care as a
mean solely (IQR 20.00; MAD 14.00) and was increased
to 48.0 days (IQR 39.88; MAD 25.41) after excluding
poor/fair quality studies.
Discussion
In this systematic review, 169 studies were included, in-
volving 11,996,479 patients. 43% of studies were of good
quality and studies variably summarised duration of pal-
liative care with inconsistent measures of spread. Inter-
nationally, half of all patients accessing palliative care
services are referred less than 19 days before death, al-
though we found very large diversity in the median dur-
ation of palliative care in days prior to death across the
countries in this review, from 6 days in Australia to 69
days in Canada. The median number of days of palliative
care prior to death for all US studies was 19 days, and
for all non-US studies, it was 29 days. Cancer patients
have a longer duration of palliative care as compared
with those with non-malignant disease. We found
palliative care duration is comparable for patients re-
ferred to specialist inpatient units and community set-
tings, but significantly longer than for patients in a
general hospital ward. At a country level, human devel-
opment index level and the extent of palliative care
development had an unexpected negative effect on the
duration of palliative care.
This large systematic review and meta-analysis of
international data found the duration of palliative care
before death for patients with life-limiting illness is
much shorter (i.e. a median of 19 days) than is supported
by research evidence and widely advocated in health care
policy. Davis et al.’s systematic review of randomised tri-
als of early integration of outpatient and home palliative
care concluded that care must be provided for at least
3–4 months before death to reach maximal benefit [5].
Although we appreciate duration and content of pallia-
tive care should be guided by individual patient needs
without a one-size-fits-all approach, we are concerned
that this reflects a gap between the current practice of
palliative care in the terminal phase of life and the timely
initiation of palliative care, which impacts on the benefit
of palliative care for patients and health care services.
This work extends previous efforts by the team to
Table 2 Duration of palliative care in days prior to death, by country and other characteristics (Continued)
Weighted median duration of
palliative care in days (IQR)
p value
Medium 66.00 (*†)
No data 6.00 (5†)
Very high 18.91 (0.09) p < 0.001
< Very high 34.00 (1.00)




No data 6.00 (5†)
4b 18.91 (0.09) p < 0.001
< 4b 28.00 (0)




Type of palliative care service Specialist palliative care unit 19.20 (17.72) p < 0.001
Community/home 20.00 (0)
General hospital ward 6.00 (0)
Combined 18.91 (0.09)
Unspecified 21.70 (167.40)
Median data weighted against the size of the study population of included studies
IQR interquartile range, UK United Kingdom, USA United States of America
*Data neither available nor possible to calculate
†IQR from single study sample
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understand the duration of hospice-based specialist
palliative care in the UK [8]. This review augments the
focus to include data across multiple care settings, in-
cluding hospital, home and the community, alongside
novel comparisons of the duration of palliative care
across countries internationally.
Variation in the duration of palliative care before death
across countries reflected a range from a median of 6
days (Australia) to 69 days (Canada). Whilst this reflects
only published data there is stark variation, with dur-
ation of palliative care encompassing only a few days
prior to death for some countries. Data from countries
may, to some extent, reflect the country-specific
provision of palliative care. For example, data from the
USA reflected patients receiving ten fewer days in pallia-
tive care than those in non-USA countries. This may be
explained by USA models of care that restrict hospice
care to patients with prognoses less than six months and
require patients to stop active treatments that may still
be beneficial [186]. Given high levels of palliative care
development and human development of included non-
USA studies, it is likely that these countries are able to
offer similar life-prolonging and supportive healthcare
interventions as the USA [187].
Longer duration of palliative care for patients with ma-
lignant disease compared with those with non-malignant
Fig. 2 Scatter plot showing individual studies according to sample size, median duration of palliative care and UNDP Human Development Index
Fig. 3 Scatter plot showing individual studies according to sample size, median duration of palliative care and WHPCA categorisation of palliative
care development
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disease, as found in this study, is consistent with a UK
report that found patients with cancer were predomin-
antly referred to palliative care services despite only ac-
counting for 29% of deaths in 2012–2013 [188]. Allsop
et al. found cancer patients had a significantly longer
median duration between referral to UK hospices and
death compared with non-cancer patients (53 days vs.
27 days, p < 0.0001) [8]. This occurs despite evidence
that palliative care needs and symptom burden are com-
parable between cancer and non-cancer groups [189,
190]. Although evidence in support of palliative care in-
terventions is predominantly from studies involving pa-
tients with cancer, this is emerging for non-cancer
groups [4]. Siouta et al. found that guidelines and path-
ways supporting the integration of palliative care in
major non-malignant disease are increasingly involving
earlier palliative care integration but lack information on
referral criteria [191]. Other barriers to accessing pallia-
tive care in this group must be understood in order to
improve integration of care.
We found palliative care duration is comparable for pa-
tients referred to specialist inpatient units and community
settings, but that this was significantly longer than for
patients referred as general hospital inpatients. This is
consistent with studies comparing the duration of pallia-
tive care between outpatient or home palliative care and
general hospital settings, and probably reflects greater re-
ferrals of patients in the last days of life in the latter setting
[10, 55, 64]. Hui et al. found that patients referred to out-
patient palliative care had improved end of life care more
than those who received inpatient palliative care from
mobile teams [55]. It may be appropriate to concentrate
efforts to increase the duration of palliative care in out-
patient settings, prior to a longer-term goal of increasing
duration of palliative care in all settings. Non-USA
patients already spend fewer days in specialist palliative
care units and more days in community palliative care,
which may reflect patient preference, or reduced capacity
of and access to inpatient settings [192].
We found a negative correlation between duration of
palliative care and country level of human development.
For the limited studies that were not categorised as ‘very
high’ according to the United Nations Human Develop-
ment Index, all but one reported data on malignant con-
ditions. The negative correlation may, therefore, partly
reflect the longer duration of palliative care for patients
with malignant disease found across all studies. How-
ever, the extent to which firm conclusions can be drawn
regarding the duration of palliative care and country
level of human development is limited. Firstly, the
predominance of malignant disease does not reflect the
current multitude of diseases and symptoms that charac-
terise health conditions requiring palliative care in the
context of low and middle-income countries [6].
Secondly, no studies were included from countries clas-
sified as ‘low’ using the United Nations Human Develop-
ment Index. This review highlights the wider need to
support increase in research capacity in the context of
low and middle-income countries (LMICs) to better
understand the provision of palliative care [6]. There
remains a disparity of the reporting of palliative care re-
search in LMICs which needs to be prioritised [193].
These are the countries in which the greatest propor-
tional rise in serious health-related suffering is projected
to occur [7]. Alongside efforts to, for example, utilise
routinely collected datasets to determine the temporal
nature of initiating and subsequent duration of palliative
care in LMICs [194], efforts to better understand opti-
mal timing and provision of palliative care in these
settings is required. It is not appropriate to extrapolate
the existing evidence for early referrals, largely from
high-income settings, to countries and settings in which
palliative care is critically absent and largely a poverty-
reduction intervention to lessen significant costs that
can be absorbed by the individual, family and local
community arising from incurable illnesses [195].
The main strength of this systematic review is the in-
clusion of a large number of studies with over 11 million
participants, giving significant power to our findings.
Duration of palliative care was difficult to define due to
the range of different palliative care settings and termin-
ology used to describe this outcome measure. We used a
complex search strategy including supplementary
searching to identify studies that used inconsistent ter-
minology for palliative care and duration of palliative
care. It was not possible to use a statistical method to as-
sess heterogeneity or publication bias. However, we con-
ducted sensitivity analyses in order to further interrogate
the data and explain any heterogeneity within the data.
Limitations included the definition of palliative care ser-
vices and the use of length-of-stay in our inclusion
criteria. Individual studies were unclear on the level of
training and experience of palliative care practitioners
and services. Therefore, we chose to assume that ser-
vices self-defining as specialist palliative care were such
but may have included some studies from services with
less specialist experience. We used length-of-stay in an
inpatient specialist palliative care setting as a proxy for
the duration of palliative care as many patients are first
referred to these settings and die during first admissions.
Across half of all length-of-stay studies included in this re-
view, the entire study population had died at the end of
the study period. However, we acknowledge that it is in-
creasingly common for patients to have short inpatient ad-
missions for symptom control with eventual discharge. In
the UK, 32% of patients admitted to inpatient hospices are
discharged [196]. As such this may not fully reflect the
breadth of input from palliative care services and patients
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admitted to inpatient hospices may have had earlier con-
tact with community or hospital palliative care services.
Consequently, the use of length-of-stay could underesti-
mate the duration of palliative care. However, our sensitiv-
ity analyses showed that studies reporting length-of-stay
did not significantly alter the overall duration of palliative
care. Studies reporting > 5% survival at the end of the
study period significantly increased the duration of pallia-
tive care for the whole dataset, suggesting that our main
finding may be an overestimation.
Conclusions
This review suggests that duration of palliative care before
death for patients with life-limiting illness is much shorter
than is supported by research evidence and widely advo-
cated in health care policy. Our study also highlights wide
variation at the level of country, across disease types and
settings to which patients are referred. This review draws
attention to the increasing extent to which palliative care
research is capturing the duration and interaction provided
to patients and their families. However, to better under-
stand the timing of palliative care provision internationally,
we welcome more consistent terminology and method-
ology, and routine assessment of duration of palliative care
from all countries, to allow benchmarking, service evalu-
ation and quality improvement. This could lead to a greater
understanding of the duration of palliative care and asso-
ciated factors. However, we acknowledge that further
research is required across all countries to understand the
mechanisms influencing differences in the duration of pal-
liative care received, across the levels of patients, caregivers,
health professionals, policymakers and the public, and the
settings in which care is provided. In particular, there is a
need for greater reporting in less developed settings where
there is a dearth of related literature and likely to be the
greatest need in future [7]. Reducing barriers to accessing
palliative care and promoting earlier integration
alongside active treatment would maximise benefits to
patients before they die and reduce costs to the wider
healthcare service.
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